Drug Trial Radar · NCT02608970
Safety and Tolerability Study of BMS-986177 in Healthy Subjects
Last checked: Nov 20, 2026Latest source record: Jul 31, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
104
Actual
Start
Dec 31, 2015
Primary completion
Jul 23, 2017
Study completion Jul 23, 2017
Sponsor
- Lead sponsor
- Bristol-Myers SquibbBristol Myers Squibb (BMY)
- Sponsor type
- Industry
- First posted
- Nov 20, 2015
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine the safety, tolerability, and pharmacokinetics of BMS-986177 in healthy subjects
Conditions
- Thrombosis
Interventions
BMS-986177Drug
PlaceboOther
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety of single dose of BMS-986177 measured by number of subjects who experience SAEs, deaths, AEs leading to discontinuation, and potential clinically significant changes in ECG parameters, vital signs, laboratory tests and physical examinationsTime frame: Approximately 3 days
- Safety of multiple dose of BMS-986177 measured by number of subjects who experience SAEs, deaths, AEs leading to discontinuation, and potential clinically significant changes in ECG parameters, vital signs, laboratory tests and physical examinationsTime frame: Approximately 16 days
- Tolerability of single dose of BMS-986177 measured by number of subjects who experience SAEs, deaths, AEs leading to discontinuation, and potential clinically significant changes in ECG parameters, vital signs, laboratory tests and physical examinationsTime frame: Approximately 3 days
- Tolerability of multiple dose of BMS-986177 measured by number of subjects who experience SAE, deaths, AEs leading to discontinuation, and potential clinically significant changes in ECG parameters, vital signs, laboratory tests and physical examinationsTime frame: Approximately 16 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
SGS Belgium NV
Antwerp, Belgium
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.